Table 2 Top 10 best-selling monoclonal antibody drugs in 2018

1

Adalimumab

(Humira)

Rheumatoid arthritis (2002)

Psoriatic arthritis (2005)

Ankylosing spondylitis (2006)

Juvenile Idiopathic Arthitis (2008)

Psoriasis (2008)

Crohn’s disease (2010)

Ulcerative colitis (2012)

Hidradenitis suppurativa (2015)

Uveitis (2018)

AbbVie

$19.9 bn

2

Nivolumab

(Opdivo)

Melanoma (2015)

Non-small cell lung cancer (2015)

Renal cell carcinoma (2015)

Head and neck squamous cell (2016)

Bristol-Myers Squibb

$7.6 bn

3

Pembrolizumab

(Keytruda)

Melanoma (2014)

Head and neck cancer (2016)

Non-small cell lung caccer (2015)

Lymphoma (2018)

Cervical cancer (2018)

Microsatellite instability-high cancer (2018)

Merck & Co

$7.2 bn

4

Trastuzumab

(Herceptin)

Breast cancer (1998)

Gastric cancer (2010)

Roche

$7.0 bn

5

Bevacizumab

(Avastin)

Colorectal cancer (2004)

Non-small cell lung caccer (2006)

Breast ERB2 negative cancer (2008)

Renal cell carcinoma (2009)

Glioblastoma (2011)

Roche

$6.8 bn

6

Rituximab,

(Rituxan)

Non-Hodgkin’s lymphoma (1997)

Chronic lymphocytic leukemia (2010)

Rheumatoid arthritis (2006)

Pemphigus vulgaris (2018)

Roche

$6.8 bn

7

Infliximab

(Remicade)

Crohn’s Disease (1998)

Rheumatoid arthritis (1999)

Ankylosing spondylitis (2004)

Ulcerative colitis (2005)

Psoriatic arthritis (2005)

Psoriasis (2006)

Johnson & Johnson

$5.9 bn

8

Ustekinumab

(Stelara)

Psoriasis (2009)

Psoriatic arthritis (2013)

Crohn’s Disease (2016)

Johnson & Johnson

$5.2 bn

9

Eculizumab

(Soliris)

Paroxysmal nocturnal hemoglobinuria (2007)

Atypical hemolytic uremic syndrome (2011)

Generalized myasthenia gravis (2017)

Neuromyelitis optica spectrum disorder (2019)

Alexion

$3.6 bn

10

Omalizumab

(Xolair)

Asthma (2003)

Chronic idiopathic urticaria (2014)

Roche

$3.0 bn